United Therapeutics Corp

UTHR remains in a Stage 4 decline with a bearish medium-term posture reinforced by lower highs & lower lows. Price trades below declining 9EMA, 20EMA, and 50DMA; oversold conditions suggest potential relief rallies, so we defer sell-side execution until a clear rejection at EMA resistance.

• ↑Q1 revenue $782M (+11% YoY) driven by Tyveso $458M (+9% YoY)
• ↑Forecasting $4B revenue run rate by end-2027 with pipeline launches
• ↓Rising PAH entrants like Eutrepia and generics pressuring market share